Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 376:221-234,280, Hauser, S.L.,et al, 2017
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
NEJM 376:209-220,280, Montalban, X.,et al, 2017
Motor Neuron Syndromes in Cancer Patients
Ann Neurol 41:722-730, 7031997., Forsyth,P.A.,et al, 1997